Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi's Eighth China Approval of PD-1 is for Renal Cell Carcinoma

publication date: Apr 9, 2024

Shanghai Junshi Biosciences was approved to market a combination of toripalimab and axitinib as a first-line treatment for medium to high risk unresectable or metastatic renal cell carcinoma (RCC). The approval makes toripalimab the first immunotherapy available for renal carcinoma in China. Toripalimab is an anti-PD-1 mAb that blocks PD-1 interactions with its ligands, PD-L1 and PD-L2 while offering an endocytosis function. In a China Phase III trial, the toripalimab-axitinib combination reported a nearly twice-as-long progression-free survival compared to sunitinib monotherapy. More details....

Stock Symbol: (HK: 1877; SHA: 688180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital